Drug Trial Radar · NCT07884864
A Clinical Study of AHB-121 in Healthy Participants and Chronic Hepatitis B (CHB) Participants
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
Oct 28, 2026
Primary completion
Apr 30, 2027
Study completion Feb 29, 2028
Sponsor
- Lead sponsor
- Ausper Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AHB-121 injection in healthy and chronic hepatitis B participants.
Conditions
- Chronic Hepatitis B Virus
Interventions
AHB-121Drug
AHB-121 will be used per week
PlaceboDrug
Placebo will be used per week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety indicatorsTime frame: Up to 18weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.